GlassScriptPhysician profile
Christopher Patrick D'Amato
NPI 1376243691
$529.94
in general payments reported to CMS, 2019-2025
12 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $286 · 2024: $63.67 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $138.05 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $76.08 | 2023 | Dupixent |
| Biofrontera INC. | $68.77 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Abbvie INC. | $42.75 | 2024 | |
| Galderma Laboratories, L.P. | $37.70 | 2024-2025 | |
| Incyte Corporation | $27.73 | 2023 | Opzelura |
| Genzyme Corporation | $25.71 | 2023 | |
| Glaxosmithkline, LLC. | $25.26 | 2025 | Nucala |
| Janssen Biotech, INC. | $24.55 | 2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $24.42 | 2023 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.55 | 2023 | Jublia |
| Lilly USA, LLC | $15.37 | 2023 | Olumiant, Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher D'Amato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.